

- 1. ことはまれなことではない。
- 2. 現在までに50を超える変異が報告されているが、日本人には235delCが高頻度で見出される。
- 3. 難聴は中等度から高度難聴が多いが、補聴器や人工内耳を用いて早期療育を行えば言語習得が可能であることを説明する。近年、この遺伝子変異を持つ患者の人工内耳の成績が良好であることが報告された。

(宇佐美真一)

Hミトコンドリア遺伝子1555変異による難聴： アミノ配糖体抗生物質による難聴

[MIM*561000；#580000]

原因 ④ ミトコンドリア遺伝 (母系遺伝) 形式を取る。ミトコンドリア12SrRNA 遺伝子1555A→G変異による。

発症 ④ ホモプラスミーであることが知られている。したがって母親が1555変異を持っている場合、その変異が子に伝えられる確率は100%。

臨床 ④ 1555A→G変異はアミノ配糖体抗生物質に対する高感受性と関連が深い。この遺伝子変異による難聴の特徴として1) 母系遺伝すること、2) 後天性、3) 両側性、4) 対称性、5) 高音障害型、6) 耳鳴を伴うことが多い、7) 聴力障害が進行する場合がある、8) また前庭症状、すなわちめまいを訴える症例はまれ。難聴の程度には個人差があるが、一般的に年齢が高いほど、またアミノ配糖体抗生物質投与歴のある患者群でより高度な難聴を呈する場合が多い。

遺伝力カウンセリング

- 1. 母系遺伝。ただし変異があっても難聴が軽度のこともあり個人差が大きく難聴の程度を予想することは難しい。また難聴は後天性で言語習得には問題とならない場合が多い。
- 2. 外来を訪れる感音性難聴患者の約3%に、アミノ配糖体抗生物質の投与歴がある患者の約1/3に変異が見出される。
- 3. アミノ配糖体抗生物質の投与歴がなくとも難聴が認められる場合があること、また難聴は進行性である場合が多く定期的に聴力検査を行い、経過観察を行うことが重要である。
- 4. 中等度以上の難聴症例には補聴器が用いられる。補聴効果の認められない高度難聴に関しては人工内耳がよい適応となることが多い。

- 5. 予防の重要性：アミノ配糖体抗生物質の投与を避けることにより高度難聴の多くは予防が可能である。薬物カードなどを利用し予防に努める。

(宇佐美真一)

Iミトコンドリア遺伝子3243変異による難聴

→ MELAS(p87, 240)の項参照

J小耳症と埋没耳 microtia : cryptotia

[MIM*251800；123557]

原因 ④ 基礎疾患 [単一遺伝子疾患 (外耳道閉鎖と伝音性難聴を伴う [MIM*251800] や染色体異常など) を伴う場合、および外因が明らかであるもの以外、ほとんどは孤発例である。まれに家族内発生例があり、多因子遺伝が想定。わが国における小耳症と埋没耳の一般頻度は各々10,000出生当たり2.1人と、1/400人。

発症 ④ 基礎疾患が否定されれば、孤発例における再発率は5%以下と低い。

臨床 ④ 耳介の大きさが小さくカップ状を呈しているI度から、外耳孔閉鎖を伴い耳介を思わせる軟骨組織が全く認められないIV度までさまざまな重症度がある。

遺伝力カウンセリング

- 1. 多因子遺伝と考えられる場合が多い。
- 2. Treacher Collins症候群 (AD) [MIM*154500]、oculo-auriculo-vertebral症候群、染色体異常症などの基礎疾患や、胎児性アルコール症候群、母体の糖尿病などの環境要因によるものを否定する。
- 3. 出生前診断は妊娠後期になれば超音波検査により、ある程度可能。

(宇佐美真一)

メニエール病 Meniere disease

[MIM#156000]

原因 内耳の内リンパ液の過剰産生，あるいは内リンパ嚢における吸収不全が原因とされる。遺伝要因の関与は不明だが，まれに家族発生の報告がある。

再発 家族内発生はまれであり，再発率はきわめて低い。

徴候 発作性の悪心・嘔吐を伴う回転性のめまい，雑聴，耳鳴。

遺伝 カウンセリング 再発率がきわめて低いことを理解させ，無用な不安を取り除く。

(宇佐美真一)

Type IX collagen knock-out mouse shows progressive hearing loss

Nobuyoshi Suzuki^a, Kenji Asamura^a, Yasutake Kikuchi^a, Yutaka Takumi^a,
Satoko Abe^b, Yasutada Imamura^c, Toshihiko Hayashi^c, Attila Aszodi^d,
Reinhard Fässler^d, Shin-ichi Usami^{a,*}

^aDepartment of Otorhinolaryngology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan

^bLaboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan

^cDepartment of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo, Tokyo 153-8902, Japan

^dMax Plank Institut für Biochemie, Department of Molecular Medicine, 85152 Martinsried, Germany

Received 29 October 2004; accepted 2 December 2004

Available online 8 January 2005

Abstract

Type IX collagen is one of the important components, together with type II, V, and XI collagens, in the tectorial membrane of the organ of Corti. To confirm the significance of type IX collagen for normal hearing, we assessed the detailed morphological and electrophysiological features of type IX collagen knock-out mice, which have recently been reported as a deafness model. Through assessment by auditory brainstem response (ABR), knock-out mice were shown to have progressive hearing loss. At the light microscopic level, the tectorial membrane of knock-out mice was found to be abnormal in shape. These morphological changes started in the basal turn and were progressive toward the apical turn. Electron microscopy confirmed disturbance of organization of the collagen fibrils. These results suggest that mutations in type IX collagen genes may lead to abnormal integrity of collagen fibers in the tectorial membrane.

© 2004 Elsevier Ireland Ltd and the Japan Neuroscience Society. All rights reserved.

Keywords: Type IX collagen; Type II collagen; Knock-out mouse; Progressive hearing loss; Tectorial membrane; Morphological change

1. Introduction

Type II and IX collagens are known to be distributed in various organs, including cartilage, the vitreous and the inner ear (Brewton and Mayne, 1994; Ricard-Blum et al., 2000). There has been growing evidence that various collagens in the inner ear are essential to maintain normal hearing. Especially, these molecules are important components of the tectorial membrane, which covers the sensory epithelium of the organ of Corti. The mammalian tectorial membrane is composed of at least four collagens, including types II, V, IX, and XI, and the non-collagenous glycoproteins alpha-tectorin, beta-tectorin, and otogelin (Slepecky et al., 1992a, 1992b, 1992c; Cohen-Salmon et al., 1997; Goodyear and Richardson, 2002). Mutations in the genes encoding these molecules localized in the tectorial

membrane have been reported to cause syndromic as well as non-syndromic hearing loss (Vikkula et al., 1995; Richards et al., 1996; Williams et al., 1996; Verhoeven et al., 1997; Mcguirt et al., 1999; Mustapha et al., 1999; Griffith et al., 2000).

To elucidate the precise role of these molecules and speculate the possible morphological and electrophysiological changes that may occur in the human inner ear, targeted disruption of the corresponding gene is an informative strategy to study the genetic disease. This strategy has been successfully applied to deafness caused by the above-mentioned genes, such as *coll1a2*-mutant mice (Mcguirt et al., 1999), *tecta*-mutant mice (Legan et al., 2000) and the *otog*-mutant mice (Simmler et al., 2000).

Recently we have shown that the homozygous type IX collagen knock-out mice show hearing loss, and are associated with abnormal shape of the tectorial membrane, in which organization of the collagen fibrils is disturbed (Asamura et al., submitted for publication). Consequent

* Corresponding author. Tel.: +81 263 37 2666; fax: +81 263 36 9164.
E-mail address: usami@hsp.md.shinshu-u.ac.jp (S.-i. Usami).

mutation screening demonstrated that possible disease-causing mutations in the *col9a3* gene were found in recessive as well as dominant non-syndromic progressive hearing loss families (Asamura et al., in press). These patients showed a moderate, all frequency involved, progressive, bilateral sensorineural hearing impairment. To explore the mechanisms of the progressive nature and predominant high frequency involvement found in the patients, the detailed morphological as well as physiological features of type IX collagen knock-out mice were examined.

2. Methods

2.1. Animals

Type IX collagen knock-out mice were created by targeted disruption of the *col9a1* gene as described by Fassler et al. (1994). In mice with an inactivated *col9a1* gene, *col9a2* and *col9a3* polypeptides are not expressed, even though the mRNAs for both *col9a* subunits are transcribed in the normal fashion (Hagg et al., 1997). *Col9a1* null mice are consequently considered to be collagen IX functional knock-out mice (Hagg et al., 1997). We recently demonstrated that the homozygous type IX collagen knock-out mice have hearing loss and are associated with abnormal shape and disturbed organization of the collagen fibrils of the tectorial membrane (Asamura et al., 2004). All animal handling procedures were in accordance with a protocol approved by the Ethics Committee of Shinshu University School of Medicine.

2.2. Auditory testing

Fifteen homozygous type IX collagen knock-out mice at 1, 3, and 6 months ($n = 5$ each) and 15 wild type mice of C57B6 strain at the same ages ($n = 5$ each) were evaluated by auditory brainstem response (ABR). The animals were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg) by intraperitoneal injection and the ABR tests were performed with a heating pad to maintain the body temperature in a soundproof room. Two different sound stimuli, click and tone burst, were performed at synthesized durations and specified amplitudes using a digital signal-processing platform (Tucker-Davis Technologies, FL, USA), and analyzed with PowerLab[®] systems (ADInstruments, Australia). Click stimuli were 0.1 ms clicks, composed of a square pulse of 0.1 ms duration. Duration of tone burst stimuli was 3.0 ms (1 ms each for rise, plateau and decay) and the center frequencies were 8, 16, 32 kHz. Stainless steel needle electrodes were placed at the vertex and ventrolateral to the left and right ears for the recording and a tweeter modified with a coupler was inserted into the external canal to deliver acoustic stimuli. ABR waveforms were recorded in 5–10 dB intervals down from a maximum amplitude of 85 dB until no waveform could be visualized.

2.3. Morphological analysis

For morphological analysis, 1 ml of fixative consisting of 4% paraformaldehyde and 2.5% glutaraldehyde in 0.1 M phosphate buffer (PB; pH 7.4) was injected into the middle ear of deeply anesthetized animals, which were then immediately perfused transcardially with the same fixative for 15 min. Cochlear tissues were post-fixed with the same fixative for 4 h, and decalcified in 0.12 M EDTA for 3 days. Then these tissues were treated with OsO_4 (in 0.1 M PBS, pH 7.4), dehydrated in graded ethanols and propylene oxide, and embedded in Durcupan (Fluka, Germany). For light microscopy, semithin sections were stained with toluidine blue. Linear measures of the height and the width of the tectorial membrane were taken according to Keiler and Richter (2001). For electron microscopy, ultrathin sections were post-stained with 1.0% uranyl acetate (10 min) and 0.3% lead citrate (5 min), and viewed on a JEOL-1200CX TEM.

3. Results

3.1. Auditory testing

Fig. 1 shows the ABR thresholds for 1-month-old wild mice and the homozygous type IX collagen knock-out mice using click and tone burst stimuli. Hearing loss in the homozygous type IX collagen knock-out mice was significant already at 1 month across all frequencies when compared to wild mice. ABR thresholds for 1-month-old wild mice were 38.0 dB (S.D. = 0) (click stimuli), 31.0 dB (S.D. = 0) (8 kHz tone burst stimuli), 35.1 dB (S.D. = 8.73) (16 kHz tone burst stimuli), and 45.5 dB (S.D. = 4.83) (32 kHz tone burst stimuli). In contrast, ABR thresholds for the homozygous type IX collagen knock-out mice were 69.7 dB (S.D. = 8.7) (click stimuli), 57.7 dB (S.D. = 7.83) (8 kHz tone burst stimuli), 80.0 dB (S.D. = 0) (16 kHz tone




Fig. 1. ABR thresholds for 1-month-old wild and homozygous type IX collagen knock-out mice. Mice were tested using click and tone burst stimuli (8, 16, 32 kHz). ABR thresholds for knock-out mice were significantly high compared to wild mice. Graphed values are mean threshold shift \pm S.D. * $P < 0.01$ (Mann-Whitney). Note that hearing impairment is significant in all frequencies.




Fig. 2. Time course of ABR thresholds for wild and homozygous type IX collagen knock-out mice using click stimuli. Note the progressive nature of hearing impairment in knock-out mice. * $P < 0.01$ (Bonferroni/Dunn test.).

burst stimuli), and 95.8 dB (SD = 13.5) (32 kHz tone burst stimuli). Differences between the two groups were statistically significant in all frequencies ($P < 0.01$). Most prominent in our data was the progressive hearing loss in knock-out mice with increasing age, in contrast with wild mice, which showed normal hearing levels until 6 months of age (Fig. 2).

3.2. Morphological analysis

The morphological abnormality, which was found to be restricted within the tectorial membrane, is already recognized in the basal turn at the age of 1 month (Fig. 3F). Such abnormality in shape was progressive and found in the middle turn at the age of 3 months (Fig. 3H).

Morphometrical analysis showed that significant difference is already noted in the basal turn at 1 month (Fig. 4C) and occurred in the middle turn at 3 months (Fig. 4B). In the apical turn, no significant difference at the light microscopic level was noted until 6 months (Fig. 4A). Electron microscopy confirmed that the tectorial membrane is composed of two different components, radial collagen fibril bundles and striated sheet matrix (Fig. 5A–C). The former fibers were predominantly found in the basal turn, and gradually decreased toward the apical turn (Fig. 5A–C). In knock-out mice, fibers were disorganized and aggregated and fused fiber-like structures were observed in all turns (Fig. 5D–F). Furthermore, many vacant regions were recognized among the disorganized fibers (Fig. 5D–F).

4. Discussion

The present morphological as well as physiological analysis showed that homozygous type IX collagen knock-out mice have progressive hearing loss. The morphological changes are correlated with the progressive hearing loss detected in ABR. The morphological changes in the tectorial membrane at the light microscopic level may be mainly due to disorganization of the collagen fibers detected by electron microscopy. With regard to the composition of the tectorial membrane, electron microscopic study indicated that it is composed of two different components, radial collagen fibril bundles and striated sheet matrix (Goodyear and Richardson, 2002). Previous immuno-electron microscopic findings further indicated that type II and IX collagens are co-




Fig. 3. Light microscopic findings of the cochlea in 1-month-old wild mice (A–C), 1-month- (D–F), 3-month- (G–I), and 6-month- (J–L) old knock-out mice. Note the crooked shaped tectorial membrane in the basal turn in 1-, 3-, and 6-month-old mice, and the middle turn in 3-, and 6-month-old mice. In the wild mouse, tectorial membrane appeared to be normal in shape until 6 months. Height (*h*) was defined as the maximum height measured on the photograph of the tectorial membrane of the cochlea, and the width (*w*) as the maximum length perpendicular to the height (A). Apical turn (A, D, G, J), middle turn (B, E, H, K), basal turn (C, F, I, L). Bar = 100 μ m.




Fig. 4. Width of the tectorial membrane of the apical turn (A), middle turn (B), and basal turn (C) for wild and homozygous type IX collagen knock-out mice. Significant difference is already noted in the basal turn at 1 month and occurred in the middle turn at 3 months. In the apical turn, no significant difference was noted until 6 months. * $P < 0.01$ (Mann–Whitney).

localized in the former collagen fibril bundles. Our recent electron microscopic study indicated that type IX collagen may contribute to the three-dimensional integrated structure of type II collagen molecules, and absence of collagen fibril bundles in homozygous type IX collagen knock-out mice. We also demonstrated that type II collagen is co-localized with type IX collagen in the tectorial membrane, but type II

collagen failed to be immunocytochemically detected in the tectorial membrane of homozygous type IX collagen knock-out mice, suggesting that a lack of type IX collagen may affect the three-dimensional structure of type II collagen molecules (Asamura et al., 2004).

Some discrepancy exists between light microscopic findings and electron microscopic findings; light microscopic morphology remained intact until 6 months in the apical turn, but electron microscopic findings demonstrated aggregated and fused collagen fiber-like structures, similar to those seen in the basal turn, in the apical turn of 1-month-old mice (Fig. 5D). This could be explained by the regional differences in composition within the tectorial membrane. A previous study indicated that collagen fibrils are not distributed homogeneously in the tectorial membrane, but there is a radial gradient of fibril concentration (Weaver and Schweitzer, 1994). According to that study, the concentration of fibrils in the limbal (inner) zone of the tectorial membrane is greater than that in the marginal (outer) zone in all of the investigated cochlear locations. This gradient is greatest in the basal, high frequency coding region of the cochlea. The present electron microscopic findings supported the predominant distribution of radial collagen fibril bundles in the basal turn (Fig. 5A–C). This could explain why the tectorial membrane in the basal turn is more prone to be crooked.

The all frequency involved, progressive nature of hearing loss found in this study was associated with the predominant and progressive morphological changes in the basal turn (and later middle turn as well). ABR thresholds obtained using tone burst stimuli of 8, 16, 32 kHz corresponded to the region which is located 40.6%, 58.6% and 75.6%, respectively, from the apex of the cochlea (Ou et al., 2000). In this respect, two-thirds of the cochlea is already functionally damaged whereas light microscopically it has a normal appearance. Such disturbance of mechanical property is due to the disorganization of the collagen fibers as described above. At the light microscopic level, the tectorial membrane of the middle turn is not crooked in 1-month-old knock-out mice. However, in the electron microscopic level, the tectorial membrane was already associated with disorganized collagen fibers. These abnormalities in collagen fibrils may result in a change of the elasticity of the tectorial membrane, which may cause moderate hearing loss at 8 kHz.

These data are well correlated with the clinical data of the patients with *COL9A3* mutations who were reported to have a moderate, all frequency involved, progressive, bilateral sensorineural hearing impairment (Asamura et al., 2004). Therefore, the data provided important aspects of progressiveness and frequency unevenness of hearing loss. Homozygous type IX collagen knock-out mice used in this study have been shown to have no detectable abnormalities at birth but to develop non-inflammatory joint diseases including severe joint disease resembling human osteoarthritis (Fassler et al., 1994; Hagg et al., 1997).




Fig. 5. Electron microscopic findings of the cochlea in 1-month-old wild mice (A–C) and homozygous type IX collagen 1-month-old knock-out mice (D–F) (A, D: apical turn; B, E: middle turn; C, F: basal turn). Tectorial membrane of wild mice shows thick fibers running in well-organized manner (A–C). The thick fibers were predominantly found in the basal turn, and gradually decreased toward the apical turn (A–C). In contrast, tectorial membrane of knock-out mice showed disorganized and aggregated/fused fiber-like structures, and vacant regions are apparent in all turns (D–F). Bar = 200 nm.

5. Conclusion

The type IX collagen knock-out mice analysis revealed progressive hearing loss, and the morphological changes in the tectorial membrane causing it to be abnormal in shape, starting in the basal turn and progressive toward the apical turn. Electron microscopy confirmed the absence of cross-striated patterns in the thick fibers and disorganization of fibrils. These results suggest that type IX collagen may be essential for an intact three-dimensional structure in association with type II collagen or with other molecules. The present study suggests that the mice are also a good animal model for progressive hearing loss caused by mutations in the gene encoding type IX collagen.

Acknowledgements

We thank Dr. Guy van Camp (University of Antwerp) and Dr. Shigeyuki Wakitani (Shinshu University) for their

critical comments, and A.C. Apple-Mathews for help in preparing the manuscript. This work was supported by the Ministry of Health and Welfare, Japan (S.U.), and a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan (S.U.).

References

- Asamura, K., Abe, S., Fukuoka, H., Nakamura, Y., Usami, S., in press. Mutation analysis of *COL9A3*, a gene highly expressed in the cochlea, in hearing loss patients. ANL.
- Brewton, R.G., Mayne, R., 1994. Heterotypic type II, IX, and XI fibrils. In: Yurchenco, P.D., Birk, D.E., Mecham, R.P. (Eds.), *Extracellular Matrix Assembly and Structure*. Academic Press, USA, pp. 129–170.
- Cohen-Salmon, M., El-Amraoui, A., Leibovici, M., Petit, C., 1997. Otogelin: a glycoprotein specific to the acellular membranes of the inner ear. *Proc. Natl. Acad. Sci. U.S.A.* 94, 14450–14455.
- Fassler, R., Schnegelsberg, P.N., Dausman, J., Shinya, T., Muragaki, Y., McCarthy, M.T., Olsen, B.R., Jaenisch, R., 1994. Mice lacking alpha 1 (IX) collagen develop noninflammatory degenerative joint disease. *Proc. Natl. Acad. Sci. U.S.A.* 91, 5070–5074.

- Goodyear, R.J., Richardson, G.P., 2002. Extracellular matrices associated with the apical surfaces of sensory epithelia in the inner ear: molecular and structural diversity. *J. Neurobiol.* 53, 212–227.
- Griffith, A.J., Gebarski, S.S., Shepard, N.T., Kileny, P.R., 2000. Audio-vestibular phenotype associated with a *COL11A1* mutation in Marshall syndrome. *Arch. Otolaryngol. Head Neck Surg.* 126, 891–894.
- Hagg, R., Hedbom, E., Mollers, U., Aszodi, A., Fassler, R., Bruckner, P., 1997. Absence of the alpha 1 (IX) chain leads to a functional knock-out of the entire collagen IX protein in mice. *J. Biol. Chem.* 272, 20650–20654.
- Keiler, S., Richter, C.P., 2001. Cochlear dimensions obtained in hemicochleae of four different strains of mice: CBA/CaJ, 129/CD1, 129/SvEv and C57BL/6J. *Hear Res.* 162, 91–104.
- Legan, P.K., Lukashkina, V.A., Goodyear, R.J., Kossi, M., Russell, I.J., Richardson, G.P., 2000. A targeted deletion in alpha-tectorin reveals that the tectorial membrane is required for the gain and timing of cochlear feedback. *Neuron* 28, 273–285.
- Mcguirt, W.T., Prasad, S.D., Griffith, A.J., Kunst, H.P., Green, G.E., Shpargel, K.B., Runge, C., Huybrechts, C., Mueller, R.F., Lynch, E., King, M.C., Brunner, H.G., Cremers, C.W., Takanosu, M., Li, S.W., Arita, M., Mayne, R., Prockop, D.J., Van Camp, G., Smith, R.J., 1999. Mutations in *COL11A2* cause non-syndromic hearing loss (DFNA13). *Nat. Genet.* 23, 413–419.
- Mustapha, M., Weil, D., Chardenoux, S., Elias, S., El-Zir, E., Beckmann, J.S., Loiselet, J., Petit, C., 1999. An alpha-tectorin gene defect causes a newly identified autosomal recessive form of sensorineural pre-lingual non-syndromic deafness DFNB21. *Hum. Mol. Genet.* 8, 409–412.
- Ou, H.C., Harding, G.W., Bohne, B.A., 2000. An anatomically based frequency-place map for the mouse cochlea. *Hear Res.* 145, 123–129.
- Ricard-Blum, S., Deblet, B., van der Rest, M., 2000. Collagen IX. In: Shterline, P. (Ed.), *Unconventional Collagens*. Oxford University Press, Oxford, pp. 73–84.
- Richards, A.J., Yates, J.R., Williams, R., Payne, S.J., Pope, F.M., Scott, J.D., Snead, M.P., 1996. A family with Stickler syndrome type 2 has a mutation in the *COL11A1* gene resulting in the substitution of glycine 97 by valine in alpha 1 (XI) collagen. *Hum. Mol. Genet.* 5, 1339–1343.
- Simmler, M.C., Zwaenepoel, I., Verpy, E., Guillaud, L., Elbaz, C., Petit, C., Panthier, J.J., 2000. Twister mutant mice are defective for otogelin, a component specific to inner ear acellular membranes. *Mamm. Genome.* 11, 960–966.
- Slepecky, N.B., Cefaratti, L.K., Yoo, T.J., 1992a. Type II and type IX collagen form heterotypic fibers in the tectorial membrane of the inner ear. *Matrix* 12, 80–86.
- Slepecky, N.B., Savage, J.E., Cefaratti, L.K., Yoo, T.J., 1992b. Electron-microscopic localization of type II, IX, and V collagen in the organ of Corti of the gerbil. *Cell Tissue Res.* 267, 413–418.
- Slepecky, N.B., Savage, J.E., Yoo, T.J., 1992c. Localization of type II, IX and V collagen in the inner ear. *Acta Otolaryngol.* 112, 611–617.
- Verhoeven, K., Van Camp, G., Govaerts, P.J., Balemans, W., Schatteman, I., Verstreken, M., Van Laer, L., Smith, R.J., Brown, M.R., Van De Heyning, P.H., Somers, T., Offeciers, F.E., Willems, P.J., 1997. A gene for autosomal dominant nonsyndromic hearing loss (DFNA12) maps to chromosome 11q22–24. *Am. J. Hum. Genet.* 60, 1168–1173.
- Vikkula, M., Mariman, E.C., Lui, V.C., Zhidkova, N.I., Tiller, G.E., Goldring, M.B., Van Beersum, S.E., De Waal Malefijt, M.C., Van Den Hoogen, F.H., Ropers, H.H., 1995. Autosomal dominant and recessive osteochondrodysplasias associated with the *COL11A2* locus. *Cell* 80, 431–437.
- Weaver, S.P., Schweitzer, L., 1994. A radial gradient of fibril density in the gerbil tectorial membrane. *Hear Res.* 76, 1–6.
- Williams, C.J., Ganguly, A., Considine, E., McCarron, S., Prockop, D.J., Walsh-Vockley, C., Michels, V.V., 1996. A-2 → G transition at the 3' acceptor splice site of IVS17 characterizes the *COL2A1* gene mutation in the original Stickler syndrome kindred. *Am. J. Med. Genet.* 63, 461–467.



Mutation analysis of *COL9A3*, a gene highly expressed in the cochlea, in hearing loss patients

Kenji Asamura^a, Satoko Abe^b, Hisakuni Fukuoka^a,
Yusuke Nakamura^b, Shin-ichi Usami^{a,*}

^a Department of Otorhinolaryngology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan

^b Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan

Received 26 October 2004; received in revised form 6 December 2004; accepted 14 January 2005

Abstract

cDNA microarray analysis indicated that *COL9A3* is one of the highly expressed genes in the cochlea. This suggests that collagen type IX has a crucial functional role in the inner ear and may be a candidate gene for hearing loss. Mutation analysis was carried out to find possible disease-causing mutations in this gene. The direct-sequencing method was applied to the *COL9A3* gene in 159 non-syndromic sensorineural deafness patients and 150 normal controls. Two possible disease-causing mutations were identified: an in-frame deletion of three amino acid residues (G181–P183 del) and a missense mutation (D617E). The patients with the mutations showed a moderate progressive bilateral sensorineural hearing impairment in all frequencies. The present data indicate that mutations of *COL9A3* may cause non-syndromic hearing impairment.

© 2005 Elsevier Ireland Ltd. All rights reserved.

Keywords: *COL9A3*; Hearing loss; Mutation screening

1. Introduction

Genes that are expressed specifically in auditory tissues are likely to be good candidates to screen for genetic alterations in patients with deafness, and several genes associated with deafness have been efficiently identified by way of organ-specific and subtractive approaches [1,2]. cDNA microarray analysis indicated that *COL9A3* is one of the highly expressed genes in the inner ear [1], suggesting that collagen type IX has a crucial functional role in the inner ear. Collagen IX is known to be one of the important components together with types II and V collagens in the tectorial membrane of the organ of Corti [3,4]. The tectorial membrane, composed of collagens and non-collagenous glycoproteins, lies over the surface of the organ of Corti and plays a crucial role in the first step of sound transduction. Type IX collagen belongs to the FACIT (fibril-associated

collagen with interrupted triplet helices) group of collagens, which is known to bind to the surface of fibril-forming type II collagen [5–7]. The alpha chain of collagen IX contains three triple helical domains (COL1, COL2, and COL3) separated by four non-triple helical (NC1–4) domains [5–7] (Fig. 1). In the present study, we performed screening for mutations in *COL9A3*, a gene reported to be one of those highly expressed in the cochlear tissues.

2. Materials and methods

2.1. Subjects

We screened 147 Japanese and 12 Korean probands with non-syndromic sensorineural hearing impairment. The composition of the subjects was as follows: 95 subjects from autosomal dominant or mitochondrial families (two or more generations affected); 15 subjects from autosomal recessive families (normal hearing parents and two or more

* Corresponding author. Tel.: +81 263 37 2666; fax: +81 263 36 9164.
E-mail address: usami@hsp.md.shinshu-u.ac.jp (S.-i. Usami).




Fig. 1. Scheme showing gene structure of *COL9A3*, which contains three triple helical domains (COL1, COL2, and COL3), separated by four non-triple helical (NC1-4) domains. Arrows indicate the mutations that have been found in this study.

affected siblings); 49 subjects with sporadic deafness (also compatible with recessive inheritance or non-genetic hearing loss). None of the patients had any other associated neurological signs. The control group consisted of 150 unrelated Japanese individuals with normal hearing evaluated by auditory testing. All subjects gave prior informed consent for participation in the project and the study was approved by the Ethical Committee of Shinshu University.

2.2. Mutation analysis

All 32 exons and flanking intronic sequences except for exon 1 of the *COL9A3* gene [8] were amplified by polymerase chain reaction PCR. Primers were designed to flank all of the exon-intron boundaries through use of the Primer3 web-based server (http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi). Each genomic DNA sample (40 ng) was amplified, using Ex-Taq polymerase (Takara), for 5 min at 95 °C, followed by 37 three-step cycles of 95 °C for 30 s, 53–63 °C for 30 s, and 72 °C for 1.5 min, with a final extension at 72 °C for 10 min, ending with a holding period at 4 °C in a Perkin-Elmer thermal cycler. The PCR products varied in size at about 230–760 bp, and they were treated with 0.1 µl exonuclease I (Amersham) and 1 µl shrimp alkaline phosphatase (Amersham) by incubation at 37 °C for 30 min, and inactivation at 80 °C for 15 min. After the products were purified, we performed standard cycle-sequencing reactions with ABI Big Dye terminators in an ABI 377 autosequencer (Applied Biosystems).

Table 1
Nucleotide changes detected by mutation analysis of the *COL9A3* gene

CHANGE	EXON	AMINO ACID	ALLELE FREQUENCY/CHROMOSOME	
			In Patients	In Control Subjects
308 G>A	5	R103Q	6/318	4/300
541-549 9bp del	11	G181-P183 del	2/318	0/300
1304 C>A	25	A435E	6/318	4/300
1649 C>T	30	P550L	2/318	0/300
1740 T>C	30	P580P	79/318	45/300
1851 C>A	31	D617E	2/318	0/300
2044 C>A	32	R2044R	16/318	Not done

3. Results

Direct DNA-sequencing identified two possible disease-causing mutations as well as five polymorphisms (Table 1). One mutation was a homozygous nine-base-pair (in-frame) deletion at position 541–549 in exon 11, removing a Gly-Pro-Hydro triplet in the 5'-end of the COL2 domain (Fig. 2). This mutation was detected in a 38-year-old female, who was affected by a moderate progressive bilateral sensorineural hearing impairment in all frequencies. Her parents were consanguineous, but not available for testing. Anamnestically, the onset of hearing impairment was at about the age of 5 and gradually progressed. She had a history of vertigo at the age of 35, but had no abnormal findings in a temporal bone CT scan. Aside from hearing loss, she was phenotypically normal. Consanguinity is a strong indication of true homozygosity and it is unlikely that the paired allele is a different large deletion leading to hemizyosity of the nine-base-pair deletion. Even if it were, the argument that this person's hearing loss is due to a defect in both *COL9A3* alleles would remain strong.

There is weaker evidence of possible dominant inheritance. This was seen in two families with a missense mutation, D617E (1851 C > A) in exon 31 (Fig. 3), localized in the COL1 domain. It was found in two (one Japanese and one Korean) independent autosomal dominant families (Fig. 3). The affected individuals with this missense mutation had moderate bilateral all frequency involved progressive sensorineural hearing loss unassociated with other symptoms. The age at onset of hearing impairment was 30 and 41 years, respectively. The probands did not have mutations in any of the other genes known to cause deafness at an appreciable frequency (*GJB2*, *SLC26A4*, or the 1555A > G mutation in the mitochondrial 12S rRNA) (data not shown).

4. Discussion

The present mutation analysis in the *COL9A3* gene detected two possible disease-causing mutations; an in-frame deletion of three amino acid residues (G181-P183 del) in the COL2 domain and a missense mutation (D617E)




Fig. 2. Electrophoregram, pedigree, and audiogram of the affected family with the G181–P183 del mutation. Electrophoregram showing the mutation in the *COL9A3* gene. Corresponding normal sequence is shown in the lower panel. Alignment of deduced amino acid sequences of the *COL9A3* genes of human, mouse, and chicken. The conserved amino acids are shown with black background and the non-conserved amino acids are shown with white background. Dot shows gap in the alignment. Arrow indicates mutation point found in the present study, showing conservation between human, mouse, and chicken.

in the COL1 domain (Fig. 1). Both mutations were found in domains, where mutations had never been reported [9–11]. The deletion in the COL2 domain appears to be recessive. The missense mutation in the COL1 domain appeared dominant. Each family was too small and only a limited number of DNA samples was available. The recessive mutation is likely a pathologic rather than a rare or functionally neutral change because: (1) it was not found in any of the controls or SNP databases (<http://snp.ims.u-tokyo.ac.jp/>), (2) it involved a deletion of amino acid residues that are all conserved in the mouse and the chicken, and (3) the pattern of audiogram (all frequency involved),

severity, and progressiveness is reminiscent of the type IX collagen knock-out mouse [12,13] (Fig. 2).

The dominant mutation (D617E) is also a candidate for pathology because: (1) it was not found in any of the controls or SNP databases (<http://snp.ims.u-tokyo.ac.jp/>), (2) it occurred at a highly conserved amino acid residue, and (3) the hearing loss is moderate and progressive, similar to the type IX collagen knock-out mouse [12,13] (Fig. 3). It is not unusual to see different mutations in the same gene having different expressions. *MYO7A* mutations, for example, are seen in both dominant and recessive families [14,15]. The association of splice mutations in exon 2 with dominantly




Fig. 3. Electrophoregrams, pedigrees, and audiograms of the affected families with the D617E mutation. Electrophoregram showing the mutation in the *COL9A3* gene. Corresponding normal sequence is shown in the lower panel. Alignment of deduced amino acid sequences of the *COL9A3* genes of human, mouse, and chicken. The conserved amino acids are shown with black background and the non-conserved amino acids are shown with white background. Arrow indicates mutation point found in the present study, showing conservation between human, mouse, and chicken.

inherited multiple epiphyseal dysplasia (MED; MIM132400) [9–11] clearly demonstrate that *COL9A3* mutations can present with dominant inheritance.

Five neutral variants, which did not fulfill the above criteria, were also found in this study (Table 1). Among them, we could not conclude whether P550L, which was localized in the NC2 domain and was detected in two independent families, is a pathologic mutation. P550L occurred at conserved amino acid residues and was not found in any of the control samples, but was not associated with the hearing loss within the family.

Collagen in the inner ear is currently of great interest, because mutations of several types of collagen have been reported to be responsible for syndromic as well as non-syndromic hearing loss (see Hereditary Hearing Loss Homepage: <http://www.uia.ac.be/dnalab/hhh/>), including Stickler syndrome (*COL2A1*, *COL11A1*, and *COL11A2*) [16–18], Alport syndrome (*COL4A3*, *COL4A4*, and *COL4A5*) [19,20], and DFNA13 (*COL11A2*) [21]. These collagens are localized in the tectorial membrane, basement membrane, spiral ligament, and the spiral limbus [3,4,22–24].

Collagen IX was known to be one of the important components, together with types II and V collagens, in the tectorial membrane of the organ of Corti [3,4]. Recently, we have demonstrated that the type IX collagen knock-out mice showed progressive hearing loss, and are associated with the abnormal shape of the tectorial membrane, in which organization of the collagen fibrils were disturbed [12,13]. These data obtained in knock-out mice are well correlated with the clinical data of the patients with *COL9A3* mutations, who were reported here to have a moderate, all frequency involved, progressive, bilateral sensorineural hearing impairment. Such characteristic audiological features closely resemble those found in patients with deafness caused by mutations in the gene encoding the collagens in the tectorial membrane (DFNA13, caused by *COL11A2* mutations and Stickler syndrome, caused by *COL2A1*, *COL11A1*, and *COL11A2* mutations), although some were reported to be non-progressive [25,26].

According to Eyre et al. [6], *COL1* and *COL2* domains are crucial to maintain the correct linear distance between type II collagen molecules. The mutations in *COL1* and *COL2* domains found in this study are predicted to affect the three-dimensional structure of the triple-helix domain of the collagen protein and may lead to abnormal integrity of collagen fibers in the tectorial membrane.

COL9A3 is known to be responsible for MED [9–11]. *COL9A3* gene mutations responsible for MED are clustered in the acceptor splice site of intron 2, resulting in the skipping of exon 3 of the *COL9A3* gene [9–11]. Whether non-syndromic hearing loss found in the present study is a continuum phenotype caused by *COL9A3* requires further discussion, because: (1) the present patients did not have short stature or early-onset osteoarthritis, characteristic features of MED and (2) hearing loss has not been reported in MED patients. However, it is noted that mutations causing

MED have only been found in the *COL3* domain, whereas mutations causing non-syndromic hearing loss were found in the *COL1* and *COL2* domains. Therefore, the phenotypic consequence is possibly positionally dependent, as postulated in *COL11A2* [21]. It is also possible that two diseases that have been classified into different categories are both part of a continuous spectrum of disease caused by *COL9A3* with overlapping phenotypes, because of their relative mild phenotypes and delayed onset.

Acknowledgements

We thank all the subjects that participated in the present project. We also thank Dr. Hee-Nam Kim (Yonsei University College of Medicine) and Dr. Tetsuo Watanabe (Oita Medical School) for sending samples of their patients, Dr. Guy van Camp (University of Antwerp), Dr. William J. Kimberling (Boys Town National Research Hospital), and Dr. Shigeyuki Wakitani (Shinshu University) for their critical comments, and A. C. Apple-Mathews for help in preparing the manuscript. This work was supported by a Health Sciences Research Grant (Research on Eye and Ear Science, Immunology, Allergy and Organ Transplantation) from the Ministry of Health and Welfare of Japan (S.U.), the Acute Profound Deafness Research Committee of the Ministry of Health and Welfare of Japan (S.U.), and a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan (S.U.).

References

- [1] Abe S, Katagiri T, Saito-Hisaminato A, Usami S, Inoue Y, Tsunoda T, et al. Identification of CRYM as a candidate responsible for nonsyndromic deafness, through cDNA microarray analysis of human cochlear and vestibular tissues. *Am J Hum Genet* 2003;72:73–82.
- [2] Abe S, Usami S, Nakamura Y. Mutations in the gene encoding KIAA1199 protein, an inner-ear protein expressed in Deiters' cells and the fibrocytes, as the cause of nonsyndromic hearing loss. *J Hum Genet* 2003;48:564–70.
- [3] Slepecky NB, Savage JE, Cefaratti LK, Yoo TJ. Electron-microscopic localization of type II, IX, and V collagen in the organ of Corti of the gerbil. *Cell Tissue Res* 1992;267:413–8.
- [4] Slepecky NB, Savage JE, Yoo TJ. Localization of type II, IX and V collagen in the inner ear. *Acta Otolaryngol* 1992;112:611–7.
- [5] van der Rest M, Mayne R. Type IX collagen proteoglycan from cartilage is covalently cross-linked to type II collagen. *J Biol Chem* 1988;263:1615–8.
- [6] Eyre DR, Wu JJ, Fernandes RJ, Pietka TA, Weis MA. Recent developments in cartilage research: matrix biology of the collagen II/IX/XI heterofibril network. *Biochem Soc Trans* 2002;30:893–9.
- [7] Wu JJ, Woods PE, Eyre DR. Identification of cross-linking sites in bovine cartilage type IX collagen reveals an antiparallel type II-type IX molecular relationship and type IX to type IX bonding. *J Biol Chem* 1992;267:23007–14.
- [8] Paasilta P, Pihlajamaa T, Annunen S, Brewton RG, Wood BM, Johnson CC, et al. Complete sequence of the 23-kilobase human *COL9A3* gene: detection of Gly-X-Y triplet deletions that represent neutral variants. *J Biol Chem* 1999;274:22469–75.

- [9] Paassilta P, Lohiniva J, Annunen S, Bonaventure J, Le Merrer M, Pai L, et al. COL9A3: a third locus for multiple epiphyseal dysplasia. *Am J Hum Genet* 1999;64:1036-44.
- [10] Bonnemann CG, Cox GF, Shapiro F, Wu JJ, Feener CA, Thompson TG, et al. A mutation in the alpha 3 chain of type IX collagen causes autosomal dominant multiple epiphyseal dysplasia with mild myopathy. *Proc Natl Acad Sci USA* 2000;97:1212-7.
- [11] Briggs MD, Chapman KL. Pseudoachondroplasia and multiple epiphyseal dysplasia: mutation review, molecular interactions, and genotype to phenotype correlations. *Hum Mutat* 2002;19:465-78.
- [12] Asamura K, Abe S, Imamura Y, Aszodi A, Suzuki N, Hashimoto S, et al. Type IX collagen is crucial for normal hearing loss. *Neuroscience*, in press.
- [13] Suzuki N, Asamura K, Kikuchi Y, Takumi Y, Abe S, Imamura Y, et al. Type IX collagen knock-out mouse shows progressive hearing loss. *Neurosci Res*, in press.
- [14] Liu XZ, Walsh J, Mburu P, Kendrick-Jones J, Cope MJ, Steel KP, et al. Mutations in the myosin VIIA gene cause non-syndromic recessive deafness. *Nat Genet* 1997;16:188-90.
- [15] Weston MD, Kelley PM, Overbeck LD, Wagenaar M, Orten DJ, Hasson T, et al. Myosin VIIA mutation screening in 189 Usher syndrome type 1 patients. *Am J Hum Genet* 1996;59:1074-83.
- [16] Williams CJ, Ganguly A, Considine E, McCarron S, Prockop DJ, Walsh-Vockley C, et al. A-2→G transition at the 3' acceptor splice site of IVS17 characterizes the COL2A1 gene mutation in the original Stickler syndrome kindred. *Am J Med Genet* 1996;63:461-7.
- [17] Richards AJ, Yates JR, Williams R, Payne SJ, Pope FM, Scott JD, et al. A family with Stickler syndrome type 2 has a mutation in the COL11A1 gene resulting in the substitution of glycine 97 by valine in alpha 1 (XI) collagen. *Hum Mol Genet* 1996;5:1339-43.
- [18] Vikkula M, Mariman EC, Lui VC, Zhidkova NI, Tiller GE, Goldring MB, et al. Autosomal dominant and recessive osteochondrodysplasias associated with the COL11A2 locus. *Cell* 1995;80:431-7.
- [19] Mochizuki T, Lemmink HH, Mariyama M, Antignac C, Gubler MC, Pirson Y, et al. Identification of mutations in the alpha 3(IV) and alpha 4(IV) collagen genes in autosomal recessive Alport syndrome. *Nat Genet* 1994;8:77-81.
- [20] Barker DF, Hostikka SL, Zhou J, Chow LT, Oliphant AR, Gerken SC, et al. Identification of mutations in the COL4A5 collagen gene in Alport syndrome. *Science* 1990;248:1224-7.
- [21] McGuirt WT, Prasad SD, Griffith AJ, Kunst HP, Green GE, Shpargel KB, et al. Mutations in COL11A2 cause non-syndromic hearing loss (DFNA13). *Nat Genet* 1999;23:413-9.
- [22] Thalmann I. Collagen of accessory structures of organ of Corti. *Connect Tissue Res* 1993;29:191-201.
- [23] Cosgrove D, Samuelson G, Pinn J. Immunohistochemical localization of basement membrane collagens and associated proteins in the murine cochlea. *Hear Res* 1996;97:54-65.
- [24] Goodyear RJ, Richardson GP. Extracellular matrices associated with the apical surfaces of sensory epithelia in the inner ear: molecular and structural diversity. *J Neurobiol* 2002;53:212-27.
- [25] De Leenheer EM, McGuirt WT, Kunst HP, Huygen PL, Smith RJ, Cremers CW. The phenotype of DFNA13/COL11A2. *Adv Otorhinolaryngol* 2002;61:85-91.
- [26] Admiraal RJ, Szymko YM, Griffith AJ, Brunner HG, Huygen PL. Hearing impairment in Stickler syndrome. *Adv Otorhinolaryngol* 2002;61:216-23.



Genetic features, clinical phenotypes, and prevalence of sensorineural hearing loss associated with the 961delT mitochondrial mutation

Katsuhiko Kobayashi^a, Tomohiro Oguchi^a, Kenji Asamura^a, Maiko Miyagawa^a,
 Satoshi Horai^{b,*}, Satoko Abe^{c,d}, Shin-ichi Usami^{a,*}

^aDepartment of Otorhinolaryngology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan

^bDepartment of Biosystems Science, The Graduate University for Advanced Studies, Hayama, Kanagawa 240-0193, Japan

^cResearch Department, R&D Center, BML, Inc., 1361-1 Matoba, Kawagoe 350-1101, Japan

^dAbe ENT Clinic, 2-2-5 Nishi-magome, Ota-ku, Tokyo 143-0026, Japan

Received 26 October 2004; received in revised form 6 December 2004; accepted 14 January 2005

Abstract

To examine the frequency of the 961delT mitochondrial point mutation, considered to be associated with aminoglycoside-induced hearing loss, restriction fragment length polymorphism (RFLP) analysis was performed in (1) 334 unrelated sensorineural hearing loss (SNHL) patients and (2) 56 patients with aminoglycoside antibiotic injection history. Approximately 2% of the SNHL patients had the 961delT mutation, raising the possibility of a relatively high prevalence of this mutation among hearing impaired populations. However, the following findings cast doubt on whether this mutation is truly associated with hearing loss: (1) a similar frequency found in the control subjects, (2) hearing loss that was not segregated within the families, (3) rates of heteroplasmy and aging that were not correlated with the severity of hearing loss, and (4) a low prevalence among the aminoglycoside-induced hearing loss patients (1/56 = 1.8%). The present analysis did not agree with the concept that the 961delT mutation causes aminoglycoside-induced hearing loss.

© 2005 Elsevier Ireland Ltd. All rights reserved.

Keywords: Mitochondria; 961delT; Hearing impairment; Aminoglycoside antibiotics

1. Introduction

Mitochondrial mutations have been demonstrated to be responsible for syndromic as well as non-syndromic hearing impairments (see Hereditary Hearing Loss Homepage [<http://dnalab-www.uia.ac.be/dnalab/hhh/>]).

One mitochondrial gene in particular, *12S rRNA*, has received much attention in relation to aminoglycoside-induced hearing loss. To date, three mutations in this gene, 1555A > G, 1494C > T, and 961delT, have been reported as possibly associated with aminoglycoside-induced hearing loss [1–6]. A series of reports have provided evidence that patients with the 1555A > G mutation have susceptibility to aminoglycosides, and subsequent hearing loss even after

exposure to small dosages [1,3,4]. The 1555A > G mutation was also demonstrated to cause hearing loss even without aminoglycoside injection, and consequently may be related to inner ear susceptibility. It may be therefore, that the mutation manifests itself as a diminished ability to repair cochlear damage from a variety of causes, including noise, aging, etc. [1,3,4]. Recently, our wide screening revealed a high frequency of the 1555A > G mutation among hearing impaired populations [7].

The 1494C > T mutation has recently been reported in a large Chinese family with maternally transmitted aminoglycoside-induced and non-syndromic deafness [6]. Clinical features indicated that the injection of aminoglycoside antibiotics induced or worsened deafness. In vitro experiments indicated significant average increase in doubling time in lymphoblastoid cell lines derived from the individuals with the 1494C > T mutation when compared to four control cell lines.

* Corresponding author. Tel.: +81 263 37 2666; fax: +81 263 36 9164.

E-mail address: usami@hsp.md.shinshu-u.ac.jp (S.-i. Usami).

* Deceased.

In contrast to the 1555A > G and 1494C > T mutations, the status of 961delT is rather ambiguous. This mutation was first reported in one out of 35 sporadic patients with a history of aminoglycoside exposure [2]. Two later reports described both a family and a single patient with aminoglycoside-induced hearing loss with this mutation [5,8]. However, little is known about the genetic features, clinical phenotypes, and frequency of this mutation among neither the hearing impaired nor the general populations. In the present study, details of the 961delT mitochondrial mutation in the hearing impaired population in Japan was evaluated.

2. Materials and methods

The frequency of the 961delT mutation was examined using restriction fragment length polymorphism (RFLP) analysis in two groups of Japanese. Group 1 consisted of 334 unrelated sensorineural hearing loss (SNHL) patients and group 2 consisted of 56 patients who had a history of aminoglycoside injection. Two control groups were employed: (1) 176 subjects who had no hearing loss as evaluated with pure tone audiometry, (2) 366 individuals from the general population from several regions in Japan. All participants in the project had provided written informed consent.

All patients had also been examined for mutations in the *GJB2* gene [MIM 121011] and the 1555A > G mutation in the mitochondrial *12S rRNA* gene [MIM 561000], both described as common causes of deafness [7,9,10].

The 334 subjects of group 1 had a mean age of 21.9 years (range: 0-78) and had visited outpatient clinics due to SNHL. Pure-tone audiograms were performed for 300 patients. Hearing of the 34 patients under 3y.o. was evaluated by auditory brainstem response (ABR) or conditioned orientation reflex audiometry (COR). Eight subjects had a history of aminoglycoside injection. There were no other associated neurological signs. The mean age of onset was 12.8 years (range: 0-76). One hundred and seventy-four subjects had a family history with one or more other family members having hearing loss (80 compatible with autosomal dominant or mitochondrial, 94 with autosomal recessive). Severity was classified by using a pure-tone average over 500, 1000, 2000 and 4000 Hz in the better hearing ear. The mean hearing level of the 300 subjects was 59.2 dB, 39% of the subjects had mild hearing loss (up to 49 dB), 22.0% had moderate (50-69 dB), 18.4% severe (70-89 dB) and 20.6% profound (90 and over dB).

The 56 patients of Group 2 had a mean age of 44.6 years (range: 2-92) and known history of aminoglycoside injection of varying dosage and duration. The mean hearing level of these patients was 72.4 dB, consisting of 16.0% mild, 17.9% moderate, 14.3% severe, and 51.8% profound hearing loss.

Restriction fragment length polymorphism (RFLP) analysis was used to identify the 961delT mutation.

MtDNA fragments were amplified using the primer pair, sense 5'-AGCATCAAGCACGCAGCAAT-3' (bases 754-773) and anti-sense 5'-GGATATGAAGCACCGCCA-3' (bases 1191-1174). After amplification, expected sizes (438 bp) of PCR products were confirmed on 2% agarose gel and digested with restriction enzyme *MnlI* (New England Biolabs, Beverly, MA, USA) at 37 °C overnight. As seen in Fig. 1, normal controls had three fragments, while in mutated DNA fragments, loss of the *MnlI* site, caused by the 961delT mutation, resulted in two fragments. The 961delT mutation was confirmed by direct sequencing using an ABI sequencer 377XL (Perkin Elmer Inc., Boston, MA, USA).

Heteroplasmy rate of the 961delT mutation was examined using a fluorescence bio-imaging analyzer FMBIOII® (Hitachi Software Engineering, Tokyo, Japan). For quantitative control, plasmids containing wild-type and 961delT mutation were prepared as follows.

The primers for detecting 961delT with the specific sites of restriction enzymes were sense *BamHI*-bases 754-773 5'-CCCGGATCCAGCATCAAGCACGCAGCAAT-3' and anti-sense bases 1191-1174-*HindIII* 5'-GGGAAGCTTGGATATGAAGCACCGCCA-3'. Prepared PCR products were inserted into pUC-18 vector (Takara, Tokyo, Japan). The PCR products and vector were digested with *BamHI* and *HindIII*. Ligation reactants were transformed into *Escherichia coli* DH5α. Positive colonies were incubated in Luria-Bertani (LB) liquid medium containing ampicillin. QIAprep spin miniprep kit (Qiagen, Valencia, CA, USA) was used for purification of plasmid DNA according to the manufacturer's protocol.

Patients' DNA samples and mixed plasmid (wild/mutant; 100%, 50%, 25%, 10%, 5%, 0%) were amplified using the sense primer with Rhodamine, sense 5'-Rho-AGCATCAAGCACGCAGCAAT-3' and anti-sense primer (same as above). Digested samples were separated by 6.0% acrylamide gel electrophoresis and visualized by a fluorescence image analyzer. These images were quantitated by Image Analysis Ver.2.0 (Hitachi Software Engineering, Tokyo, Japan) (Fig. 2). All analyses were performed in duplicate.




Fig. 1. Restriction patterns of the patients with 961delT mutation (right) and wild type (left). The restriction enzyme divides normal PCR products into three fragments, while in mutated DNA there are two fragments, due to loss of the *MnlI* site, caused by the 961delT mutation.




Fig. 2. Digested samples visualized by a fluorescence image analyzer. The left six lanes are mixed plasmid (ratio of mutant: 100%, 50%, 25%, 10%, 5%, 0%, respectively), and the right six lanes are the patients with the 961delT mutation (four lanes) and wild type (two lanes).

3. Results

3.1. Frequency

The 961delT mutation was recognized in 7/334 (2.1%) in the unrelated hearing impaired patients (group 1) and 1/56 (1.8%) in the patients with aminoglycoside injection history (group 2). This mutation was also detected in 2/176 (1.1%) in the subjects without hearing loss (control 1) and 8/366 (2.2%) in the general population (control 2). There were no statistically significant differences between the groups (Mann–Whitney *U*-test).

3.2. Heteroplasmy rate

As illustrated in Fig. 1, digested samples visualized on an agarose gel represented a homoplasmic pattern. The precise rate of heteroplasmy assessed by a fluorescent image analyzer was from 97% to 100%.

3.3. Segregation

Available pedigrees of the patients associated with the 961delT mutation are shown in Fig. 3. One patient was found in a dominant family, three patients were found in recessive families, and one patient was found in a simplex family. Pedigrees indicated that hearing loss phenotype is not associated with the 961delT mutation.

3.4. Hearing assessment

The mean hearing level of the patients with the 961delT mutation was 34.7 dB, 66.7% of the subjects had mild hearing loss (up to 49 dB), 22.2% had moderate (50–69 dB), 5.6% severe (70–89 dB) and one patient had profound (90 and over dB) loss. Overlapping audiograms collected from the subjects who had the 961delT mutation are shown in Fig. 4. There is a wide variety of hearing impairment from normal to high frequency predominant and mild to severe.

3.5. Other involved genes

All patients with the 961delT mutation had been examined for mutations in the *GJB2* gene and the 1555A > G mutation in the mitochondrial *12S rRNA* gene. Among the 334 unrelated hearing loss subjects, 13 patients (3.9%) had mutations in the *GJB2* gene and nine patients (2.7%) had the 1555A > G mutation. Among the 56 patients with known aminoglycoside antibiotic injection, 11 patients (19.6%) had the 1555A > G mutation. These frequencies together with the 961delT mutation are summarized in Table 1. None of the patients had both the 961delT and the 1555A > G mutations, but one patient was associated with homozygous 235delC and the 961delT mutations and showed profound hearing loss (asterisks in Fig. 4).

4. Discussion

4.1. Frequency

Approximately 2% of patients with SNHL possessed the 961delT mutation, suggesting the possibility that it may have an important contribution to the etiology of hearing loss patients in Japan. However, a similar frequency was also found in the control populations, raising the question of whether the 961delT mutation is a sole cause of hearing loss or not. In this study, we used two different control groups: control 1 consisting of subjects in whom pure tone audiometry confirmed the absence of hearing loss, and control 2 who were randomly selected from the general population in Japan. Although the mutation frequency (1.1%) in control 1 seemed to be somewhat lower than that in SNHL patients (2.1%), statistical assessment did not show any significant difference ($p = 0.509$; Mann–Whitney *U*-test). Moreover, a similar frequency was found in the general population (2.2%), indicating that the 961delT mutation is commonly found in the general population.

4.2. Relationship to aminoglycoside ototoxicity

In this study, only one out of the 56 patients (1.8%) with a history of aminoglycoside injection had the 961delT mutation, therefore the significance of this mutation in relation to aminoglycoside-induced hearing loss was not evident. This is in contrast to the 1555A > G mutation, which was present in only 2.7% (9/334) in group 1, but in 19.6% (11/56) in group 2. This high frequency of the 1555A > G mutation among patients with a history of aminoglycoside injection is compatible with our previous report [10], and further confirmed the high genetic susceptibility of this mutation to aminoglycoside ototoxicity.

4.3. Segregation

We were unable to find any families similar to that reported by Casano et al., in which hearing loss and the




Fig. 3. Pedigrees with individual subjects' audiograms. "M" indicates patients associated with the 961delT mutation. Note that even though the 961delT mutation is inherited through the mother, hearing loss is not. One patient (asterisk) of family #4 was homozygous for the 235delC mutation in the *GJB2* gene.

mutation were co-segregated [5]. As shown in Fig. 3, hearing loss phenotype was not associated with the 961delT mutation, indicating that hearing loss may possibly occur independently of the 961delT mutation.

4.4. Clinical phenotypes

Concerning phenotypes caused by the 961delT mutation, two previous reports described moderate to severe high frequency-involved SNHL [5,8]. In contrast, in this study,

overlapping audiograms collected from the subjects with the 961delT mutation showed a wide variety of hearing impairment from normal to high frequency involved mild to severe hearing loss (Fig. 4). It is unlikely from the present results that the 961delT mutation solely causes hearing loss. It may be that the rate of aging and/or heteroplasmy contributes to the severity of hearing loss. To assess this possibility, overlapping audiograms were divided into four age groups: 0–19, 20–39, 40–59 and over 59. However, the severity of hearing loss was independent of age (data not




Fig. 4. Overlapping audiograms from subjects with the 961delT mutation. There is a wide variety of hearing impairment from normal to mild to severe hearing loss. One patient was associated with homozygous 235delC mutations (asterisks).

shown). With regard to the rate of heteroplasmy, all the samples were between 97% and 100%, and there were no large variations that could have caused such a variety of hearing levels.

4.5. Other involved genes

One patient with the 961delT mutation was also associated with homozygous 235delC mutations. The patient showed profound hearing loss (asterisks in Fig. 4), in agreement with reports of the *GJB2* mutations causing moderate to severe hearing loss [11]. Recent genotype/phenotype correlation study in the Japanese revealed that most of the patients with the 235delC mutation showed comparatively more severe hearing loss [12].

In conclusion, the present detailed genetic as well as clinical analysis using a relatively large cohort did not agree with the concept that the 961delT mutation causes aminoglycoside-induced hearing loss. Such discrepancy with conclusions from previous studies may have occurred because of the difference in applied techniques and control evaluation.

The first report by Bacino et al. used SSCP and heteroduplex methods [2], which are more indirect and insensitive approaches, to identify the 961delT mutation. Therefore, they may have passed over a subtle base change including the 961delT mutation as also suggested by Tang et al. [13]. The following two case reports lacked control evaluation [5,8] as well as segregation analysis [8], which must be performed to prove that a mutation is disease causing. Recently, three nucleotide changes, 961T > G, 956-960insC, and 961insC, in the vicinity of the nucleotide 961 were reported [13,14]. These data suggested that this region may be more variable, and therefore a careful assessment will be needed to discuss whether these changes are associated with disease or not.

Acknowledgments

We thank all the subjects that participated in the present project. We would also like to thank Ms. Yukari Nakamura, Ms. Naoko Anaguchi, and Ms. Yumi Saito for technical assistance, Ms. A.C. Apple-Mathews for help in preparing the manuscript, and Dr. Yoshimitsu Fukushima for providing normal control samples. This study was supported by a Health Sciences Research Grant (Research on Eye and Ear Science, Immunology, Allergy and Organ Transplantation) from the Ministry of Health and Welfare of Japan and by the Acute Profound Deafness Research Committee of the Ministry of Health and Welfare of Japan. To our great sorrow, our co-author Dr. Satoshi Horai passed away suddenly during the preparation of this paper. We are grateful for his contributions to our project and pray for the repose of his soul.

References

- [1] Prezant TR, Agopian JV, Bohlman MC, Bu X, Oztas S, Qiu WQ, et al. Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. *Nat Genet* 1993;4:289-94.
- [2] Bacino C, Prezant TR, Bu X, Fournier P, Fischel-Ghodsian N. Susceptibility mutations in the mitochondrial small ribosomal RNA

Table 1
Frequencies of the 961delT and 1555A > G mutations in patients and controls

Subjects	n	961delT	1555A>G
Group 1 (SNHL patients without selection bias)	334	7 (2.1%)	9 (2.7%)
Group 2 (SNHL patients with history of aminoglycoside injection)	56	1 (1.8%)	11 (19.6%)
Control 1 (subjects with no hearing loss)	176	2 (1.1%)	
Control 2 (general population)	366	8 (2.2%)	

- gene in aminoglycoside induced deafness. *Pharmacogenetics* 1995;5:165-72.
- [3] Usami S, Abe S, Kasai M, Shinkawa H, Moeller B, Kenyon JB, et al. Genetic and clinical features of sensorineural hearing loss associated with the 1555 mitochondrial mutation. *Laryngoscope* 1997;107:483-90.
- [4] Estivill X, Govea N, Barcelo E, Badenas C, Romero E, Moral L, et al. Familial progressive sensorineural deafness is mainly due to the mtDNA A1555G mutation and is enhanced by treatment of aminoglycosides. *Am J Hum Genet* 1998;62:27-35.
- [5] Casano RA, Johnson DF, Bykhovskaya Y, Torricelli F, Bigozzi M, Fischel-Ghodsian N. Inherited susceptibility to aminoglycoside ototoxicity: genetic heterogeneity and clinical implications. *Am J Otolaryngol* 1999;20:151-6.
- [6] Zhao H, Li R, Wang Q, Yan Q, Deng JH, Han D, et al. Maternally inherited aminoglycoside-induced and nonsyndromic deafness is associated with the novel C1494T mutation in the mitochondrial *12S rRNA* gene in a large Chinese family. *Am J Hum Genet* 2004;74:139-52.
- [7] Usami S, Abe S, Akita J, Shinkawa H, Kimberling WJ. Sensorineural hearing loss associated with the mitochondrial mutations. *Adv Otorhinolaryngol* 2000;56:203-11.
- [8] Yoshida M, Shintani T, Hirao M, Himi T, Yamaguchi A, Kikuchi K. Aminoglycoside-induced hearing loss in a patient with the 961 mutation in mitochondrial DNA. *ORL J Otorhinolaryngol Relat Spec* 2002;64:219-22.
- [9] Abe S, Usami S, Shinkawa H, Kelley PM, Kimberling WJ. Prevalent connexin 26 gene (*GJB2*) mutations in Japanese. *J Med Genet* 2000;37:41-3.
- [10] Usami S, Abe S, Akita J, Namba A, Shinkawa H, Ishii M, et al. Prevalence of mitochondrial gene mutations among hearing impaired patients. *J Med Genet* 2000;37:38-40.
- [11] Cryns K, Orzan E, Murgia A, Huygen PL, Moreno F, del Castillo I, et al. A genotype-phenotype correlation for *GJB2* (connexin 26) deafness. *J Med Genet* 2004;41:147-54.
- [12] Oguchi T, Ohtsuka A, Hashimoto S, Oshima A, Abe S, Kobayashi Y, et al. Clinical features of patients with *GJB2* (connexin 26) mutations: severity of hearing loss is correlated with genotypes and protein expression patterns. *J Hum Genet*, in press.
- [13] Tang HY, Hutcheson E, Neill S, Drummond-Borg M, Speer M, Alford RL. Genetic susceptibility to aminoglycoside ototoxicity: how many are at risk? *Genet Med* 2002;4:336-45.
- [14] Li R, Xing G, Yan M, Cao X, Liu XZ, Bu X, et al. Cosegregation of C-insertion at position 961 with the A1555G mutation of the mitochondrial *12S rRNA* gene in a large Chinese family with maternally inherited hearing loss. *Am J Med Genet* 2004;124A:113-7.

AUDIOLOGICAL FEATURES AND MITOCHONDRIAL DNA SEQUENCE IN A LARGE FAMILY CARRYING MITOCHONDRIAL A1555G MUTATION WITHOUT USE OF AMINOGLYCOSIDE

TATSUO MATSUNAGA, MD, PHD

TOKYO, JAPAN

HIROSHI KUMANOMIDO, MD

TOCHIGI, JAPAN

YU-ICHI GOTO, MD, PHD

TOKYO, JAPAN

MASAE SHIROMA, PHD

TOCHIGI, JAPAN

SHIN-ICHI USAMI, MD, PHD

MATSUMOTO, JAPAN

To elucidate the pathophysiological and genetic mechanisms of hearing loss associated with the homoplasmic mitochondrial A1555G mutation in the absence of aminoglycoside exposure, we conducted audiological and genetic analyses on 67 maternally related members of a large Japanese family carrying this mutation. A consistent pattern was evident in the audiograms, with features of sensory presbycusis, cochlear origin at all levels of hearing loss, and a high degree of vulnerability of outer hair cells. That the degree of hearing loss was similar in affected subjects within the same sibling group but differed between sibling groups suggests the involvement of nuclear modifier genes. Total mitochondrial DNA sequences were completely identical among subjects with various levels of hearing loss, and lacked additional pathogenic mutations. For the diagnosis of sensorineural hearing loss, the mitochondrial A1555G mutation should be considered when these features are present even in the absence of aminoglycoside exposure.

KEY WORDS — cochlea, hereditary hearing loss, mitochondria, nonsyndromic hearing loss.

INTRODUCTION

Various mitochondrial DNA mutations have been reported to cause hearing loss, either on their own or in association with other clinical symptoms such as neuromuscular disorders and diabetes.¹ The homoplasmic A1555G mutation in the mitochondrial 12S ribosomal RNA gene has been the first mitochondrial DNA mutation to be associated with nonsyndromic sensorineural hearing loss.² The A1555G mutation was initially identified primarily in subjects with hearing loss following aminoglycoside exposure. Indeed, it has been reported that the increased binding affinity of ribosomal RNA to aminoglycosides as a result of the mutation constitutes the pathogenetic mechanism underlying ototoxic susceptibility.³ Subsequently, this mutation was also found in subjects who developed hearing loss in the absence of aminoglycoside exposure.⁴⁻⁸ In these cases, the clinical phenotype ranged from profound congenital hearing loss to moderate progressive hearing loss of later onset to only slight hearing loss. Although these phenotypic differences may be the result of additional mutations in the mitochondrial or nuclear DNA, or of unknown

environmental factors, the exact mechanism has not been determined. Furthermore, the pathophysiological mechanism of hearing loss due to the A1555G mutation in the absence of aminoglycoside exposure has not been defined, because there are no reports on temporal bone histopathology in patients with this mutation, and the audiological evaluation of patients has been limited to pure tone audiometry (PTA) in most previous studies. Only one study carried out detailed audiological evaluations, but most subjects exhibited profound hearing loss.⁹ Thus, such detailed audiological evaluations of subjects with various levels of hearing loss, especially those with mild or moderate hearing loss, remain to be performed to uncover the pathophysiological mechanism underlying the development of hearing loss.

We previously identified a large Japanese family in which the A1555G mutation is prevalent. None of the family members were previously exposed to aminoglycosides, and the prevalence of hearing loss in maternally related members was much higher than that in the general population.¹⁰ To further elucidate the pathophysiological and genetic mechanisms of

From the Department of Otolaryngology, National Tokyo Medical Center (Matsunaga), and the Department of Mental Retardation and Birth Defect Research, National Center of Neurology and Psychiatry (Goto), Tokyo, the Department of Speech-Language Pathology and Audiology, School of Health Science, International University of Health and Welfare, Tochigi (Matsunaga, Kumanomido, Shiroma), and the Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto (Usami), Japan. This work was supported by a Health Science Research Grant from the Ministry of Health, Labor and Welfare of Japan.

CORRESPONDENCE — Tatsuo Matsunaga, MD, PhD, Dept of Otolaryngology, National Tokyo Medical Center, Higashigaoka 2-5-1, Meguro-ku, Tokyo 152-8902, Japan.